Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A PHASE3 clinical study on Nasopharyngeal Carcinoma, this trial is ongoing. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 9 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Treatment cycles of chemotherapy will be at most 6 weeks which will be decided by investigators. Progression-free survival (PFS) determined by the Independent Review Committee (IRC) will be the primary outcome measures.
In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Treatment cycles of chemotherapy will be at most 6 weeks which will be decided by investigators. Progression-free survival (PFS) determined by the Independent Review Committee (IRC) will be the primary outcome measures.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
May 2022 — Sep 2022 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — May 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .